Last Updated : April 25, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Symdeko | tezacaftor/ivacaftor | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
Tezspire | tezepelumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | |||
Brilinta | Ticagrelor | Acute coronary syndromes | Do not list | Complete | ||
Brilinta | ticagrelor | Prevention of atherothrombotic events with history of myocardial infarction | Reimburse with clinical criteria and/or conditions | Complete | ||
Ilumya | tildrakizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Inspiolto Respimat | Tiotropium / olodaterol | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
Spiriva Respimat | Tiotropium bromide | Chronic obstructive pulmonary disease | List with clinical criteria and/or conditions | Complete | ||
Aptivus | Tipranavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
TBC | tirzepatide | Diabetes mellitus, type 2 | Cancelled |